Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change + Annual Report + AGM notice

27 Jun 2012 07:00

RNS Number : 1954G
Byotrol PLC
27 June 2012
 



27 June 2012

 

Byotrol plc

 

Directorate changes and posting of Annual Report

and Notice of Annual General Meeting

 

 

Byotrol plc ('Byotrol' or the "Company"), the developer of anti-microbial hygiene technologies, announces that, at the Annual General Meeting, Adrian Smith, Stephen Falder and Richard Bell will retire from the Board. Stephen Falder will continue to support the Company on technical and business development matters. Richard Bell will continue as Company Secretary. The Board thanks its retiring members for their contribution during their years as Directors.

 

At the Annual General Meeting, a resolution will be proposed to appoint Duncan Grosvenor as a Director of the Company. Duncan will become Finance Director. He joined the Company in October 2011 as Head of Finance and is a Fellow of the Association of Chartered Certified Accountants. He also has an MBA from Oxford Brookes University.

 

The annual report for the year ended 31 March 2012 and the notice of its Annual General Meeting ("AGM") have been sent to shareholders and both documents are available to download from the Company's website at www.byotrol.co.uk.

 

The AGM will be held at 2.30pm on 19 July 2011 at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

 

 

Enquiries:

 

Byotrol plc 01925 742000

Gary Millar, Chief Executive

Richard Bell, Finance Director

 

finnCap Limited 020 7220 0500

Nominated Adviser and broker

Geoff Nash/Christopher Raggett

 

Winningtons 020 3176 4722

Tom Cooper / Paul Vann 0797 122 1972

 

 

Mr Grosvenor, aged 34, currently holds, and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than the Company:

 

Current Directorships/Partnerships

Past Directorships/Partnerships (in the last five years)

None

New Horizons Global Limited

 

Mr Grosvenor was a director of New Horizons Global Limited from April 2010 to September 2011. New Horizons Global Limited entered into a creditors' voluntary arrangement in June 2011 to repay its creditors in full over a twelve month period by instalments.

 

There are no other matters to be disclosed under paragraph (g) of Schedule 2 of the AIM rules.

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a standalone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGUGWQUPPGAQ
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.